The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Media (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.48
Ask: 1.55
Change: 0.015 (1.00%)
Spread: 0.07 (4.73%)
Open: 1.50
High: 1.50
Low: 1.50
Prev. Close: 1.50
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential

#HEMO are a London-listed, US-based biotech company developing two revolutionary blood cancer treatments.

CDX antibodies are intended to remove the need for chemo and radiation before a bone marrow transplant is done. The potential market for this treatment is worth $8/9 billion annually. Lake Pharma have been signed-up to create antibodies for the clinical trial phase which will take place 'within 16 months'.

Hu-PHECS are Hemo's second product candidate, and CEO and co-Founder Dr Vladislav Sandler hopes their recent academic collaboration with Oxford University will create 'a new opportunity' for his company. The new treatment will turn dormant blood cells into active ones, ready for a bone marrow transplant and does away with the requirement to find a matching donor. 40% of people currently can't find a donor.

This product is 24 to 36 months from clinical trials. Both treatments have achieved proof of principle status.

Related Hemogenyx Media

What's Hot 19th September 2023

What's Hot at Easter

RNS EXCLUSIVE: HemoGenyx release successful CDX Antibody first data results

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.